Patel R, Newman E M, Villacorte D G, Sato J K, Reaman G H, Finklestein J Z, Krailo M D, Hammond G D, Holcenberg J S
Division of Hematology-Oncology, Children's Hospital, Los Angeles, California 90054.
Cancer Res. 1991 Sep 15;51(18):4871-5.
Because of the synergy seen in adult trials when 5-fluorouracil is combined with leucovorin, we initiated a Phase I trial of this combination in children's refractory cancer. Leucovorin, an equal mixture of the (6R,S)-diastereoisomers, was administered p.o. for 6 consecutive days as 4 equal doses at 0, 1, 2, and 3 h totaling 500 mg/m2/day. 5-Fluorouracil was given daily on days 2 to 6 as an i.v. bolus immediately following the last dose of leucovorin. The leucovorin dose was held constant while the 5-fluorouracil dose was escalated in cohorts of patients from 300 mg/m2/day to its maximally tolerated dose. Thirty-five patients (19 with acute leukemia and 16 with solid tumors) were evaluable for toxicity. The maximally tolerated dose of FUra was 450 mg/m2/day for 5 treatments for patients with solid tumors and 650 mg/m2/day for 5 treatments for the children with leukemia. The dose-limiting toxicities were myelosuppression and stomatitis. Other side effects included transient, mild elevations of serum transaminases, mild nausea, vomiting, and diarrhea. The pharmacokinetics of high-dose p.o. leucovorin was studied in 23 children. There was considerable interpatient variability in the plasma concentrations of total bioactive folates (TBAF), (6S)-leucovorin, and (6S)-5-methyltetrahydrofolic acid. The maximum plasma concentration (Cmax) of TBAF was 821 +/- 97 (SE) nM, occurring at a median of 8 h; the Cmax of (6S)-leucovorin was 77 +/- 11 nM, occurring at 4 h. The TBAF concentration fell to 146 +/- 42 nM by 24 h. (6S)-5-Methyltetrahydrofolic acid accounted for 90 +/- 7% of the TBAF at the Cmax. The plasma concentration of (6R)-leucovorin, the unnatural isomer, was equal to that of TBAF. Thus, p.o. leucovorin reduced the 5-fold excess of (6R)-leucovorin over TBAF seen after i.v. doses. The relative amounts of the three major plasma species were approximately the same as in adults, even though the Cmax of each compound was lower.
由于在成人试验中观察到5-氟尿嘧啶与亚叶酸联合使用时具有协同作用,我们开展了一项针对儿童难治性癌症的该联合用药I期试验。亚叶酸为(6R,S)-非对映异构体的等量混合物,口服给药,连续6天,分4次等量剂量,于0、1、2和3小时给药,总量为500mg/m²/天。5-氟尿嘧啶在第2至6天每天给药,在最后一剂亚叶酸后立即静脉推注。亚叶酸剂量保持不变,而5-氟尿嘧啶剂量在患者队列中从300mg/m²/天逐步增加至最大耐受剂量。35例患者(19例急性白血病患者和16例实体瘤患者)可进行毒性评估。实体瘤患者5-氟尿嘧啶的最大耐受剂量为450mg/m²/天,给药5次;白血病患儿的最大耐受剂量为650mg/m²/天,给药5次。剂量限制性毒性为骨髓抑制和口腔炎。其他副作用包括血清转氨酶短暂轻度升高、轻度恶心、呕吐和腹泻。对23名儿童进行了高剂量口服亚叶酸的药代动力学研究。患者之间总生物活性叶酸(TBAF)、(6S)-亚叶酸和(6S)-5-甲基四氢叶酸的血浆浓度存在相当大的差异。TBAF的最大血浆浓度(Cmax)为821±97(SE)nM,中位出现时间为8小时;(6S)-亚叶酸的Cmax为77±11nM,出现时间为4小时。到24小时时,TBAF浓度降至146±42nM。在Cmax时,(6S)-5-甲基四氢叶酸占TBAF的90±7%。非天然异构体(6R)-亚叶酸的血浆浓度与TBAF相等。因此,口服亚叶酸减少了静脉给药后(6R)-亚叶酸相对于TBAF出现的5倍过量。尽管每种化合物的Cmax较低,但三种主要血浆成分的相对含量与成人大致相同。